Daiichi Sankyo Company, Limited

Sumitomo Bakelite Company Limited

Kokuyo Co., Ltd.

Takano Co., Ltd.

Saitama Medical University

The University of Tokyo

Ushio Denki Kabushiki Kaisha

Mie University

Kobe University

Kensuke Nakamura

Tomoko Terauchi

Takao Sugano

Mitsuhiro Iwamoto

Kenta Shiozawa

Takeshi Masuda

Hiroaki Uchida

Takashi Nakada

Yusuke Ota

Shinji Ashida

Daisuke Okajima

Ichiro Hayakawa

Narihiro Toda

Hirofumi Hamada

Masaki Meguro

Fuminao Doi

Tomoaki Ichikawa

Yoshirou Kawaguchi

Naoya Harada

Kenji Iida

Toshiki Yajima

Toru Meura

Kenji Osawa

Shinnosuke Tsuji

Sho Tsukamoto

Takenobu Katagiri

Shiho Kozuma

Junya Ichikawa

Tsuyoshi Hirata

Atsuko Saito

Takehiro Hirai

Hitoshi Aoki

Yojiro Kinoshita

Ryuji Hashimoto

Takashi Isobe

Hiroshi Shiku

Toshiyuki Shimizu

Takeshi Hosomi

Takahiro Hiraoka

Kensuke Miyake

Toshiaki Ohtsuka

Takaichi Shimozato

Hiroshi Hirose

Ichiro Watanabe

Makiko Nakayama

Yasuhiro Shibamoto

Naoya Shinozaki

Kento Tanaka

Chigusa Yoshimura

Takashi Kagari

Atsuo Kanno

Jun Ishiguro

Yasushi Akahori

Ryuta Mukasa

Yuji Motoi

Yoji Ishimura

Yusuke Murakami

Umeharu Ohto

Atsushi Manno

Ayaka Yatsu

Shinji Furuzono

Naoyuki Makita

Sumie Muramatsu

Tohru Takahashi

Masahiro Wada

Takanori Samejima

Hitoshi Kawaguchi

Yasunori Ono

Takayoshi Kanou

Kenta Asano

Katsuaki Hayashi

Toyosei Takahashi

Masato Amano

Fei Xu

Kenya Tachibana

Hironori Maruyama

Yukiko Sekiguchi

Iji Onozuka

Yoshitaka Okugawa

Hideki Hara

Ryoichi Okada

Masaaki Kato

Kazuyuki Yoshizaki

Chikako Suzuki

Tomoko Shibutani

Mayumi Sue

Takashi Matozaki

Ryouichi Okada

Naoya Niimura

Kazuki Tsukadaira

Shinichiro Itoh

Hanako Ito

Teppei Ito

The dielectric barrier discharge plasma generator includes: a dielectric substrate that exhibits a plate shape extending in a first direction and has a first surface and a second surface located on an opposite side of the first surface in a second direction orthogonal to the first direction; a first electrode disposed on the dielectric substrate on a side of the first surface; a second electrode disposed at a position separated from the second surface of the dielectric substrate in the second direction; a gas flow path that is formed by a gap between the dielectric substrate and the second electrode and through which a gas flows in a third direction orthogonal to the first direction and the second direction; and an outlet provided at a first end which is one end portion of the gas flow path in the third direction.

Dielectric barrier discharge plasma generator

The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate

An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Bispecific antibody

Provided are novel antibody-pyrrolodiazepine derivative and novel antibody-pyrrolodiazepine derivative conjugates, as well as methods of using the same, and a novel CLDN6 and/or CLDN9 antibody. The disclosed compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics, and include substituted benzo[e]pyrrolo[1,2-α][1,4]diazepine.

Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines

It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.

Polynucleotides encoding antibodies which bind the EC3 domain of cadherin-6 (CDH6) and possess internalization ability

A dielectric barrier plasma generator includes: a dielectric substrate, a high-voltage electrode provided on a first surface of the dielectric substrate, a low-voltage electrode provided to face a second surface of the dielectric substrate, a power introduction section provided at a first end of the high-voltage electrode, a gas channel formed from a first end to a second end thereof between the dielectric substrate and the low-voltage electrode to allow gas to flow from the first end of the gas channel to the second end thereof, and a blowout outlet formed at the second end of the gas channel to blow out the gas that has flown through the gas channel and plasma that has been generated in the gas channel. The dielectric substrate includes a portion having a thickness being thinner when being closer to the blowout outlet.

Dielectric barrier plasma generator and plasma discharge starting method for dielectric barrier plasma generator

Provided are methods for treatment or prevention of an autoimmune disease that comprise administering a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.

Methods for treating autoimmune diseases incorporating an anti-LAG3 antibody

An anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47.

Anti-SIRPalpha antibody

A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].

Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-&#x3b1;][1,4]diazepines

The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.

Anti-CD3 antibody and molecules comprising the antibody

Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor

The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.

Anti-human TLR7 antibody

A chair includes a leg, a seatincluding a pressure receiving surface PS, a backrest, and a support mechanism SM. The seatcan move in the front-rear or left-right direction along a predetermined trajectory and to downwardly incline a tip side of the seatin a movement direction in accordance with a movement of the seatfrom a predetermined reference position (S). The support mechanism SM includes a return-force generation unit configured to generate, in accordance with an amount of movement, a return force in a direction in which the seatmoved from the reference position (S) in the front-rear or left-right direction is returned to the reference position (S), and movably supports the backrestin the left-right direction together with a movement of the seatin the left-right direction.

Chair

This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).

Anti-ALK2 antibody

Growing community of inventors

Tokyo, Japan

Kensuke Nakamura